Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0JNVJY
ADC Name
Ch14.18-MMAF
Synonyms
Ch14.18 MMAF
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Neuroblastoma [ICD11:2A00]
Investigative
Drug-to-Antibody Ratio
4.1
Antibody Name
Anti-GD2 mAb ch14.18
  Antibody Info 
Antigen Name
Ganglioside GD2 (GD2)
  Antigen Info 
Payload Name
Monomethyl auristatin F
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-Val-Cit-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
McMMAF
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 58.74
%
EL4 cells
Thymoma
Tumor Growth Inhibition value (TGI) 
≈ 74.95
%
B78-D14 cells
Amelanotic melanoma
Revealed Based on the Cell Line Data
Click To Hide/Show 38 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.05
nM
B78-D14 cells
Amelanotic melanoma
Half Maximal Inhibitory Concentration (IC50) 
0.06
nM
EL4 cells
Thymoma
Half Maximal Inhibitory Concentration (IC50) 
0.81
nM
IMR-32 cells
Neuroblastoma
Half Maximal Inhibitory Concentration (IC50) 
1.27
nM
COLO 38 cells
Amelanotic melanoma
Half Maximal Inhibitory Concentration (IC50) 
1.84
nM
T98G cells
Glioblastoma
Half Maximal Inhibitory Concentration (IC50) 
3.3
nM
U2OS cells
Osteosarcoma
Half Maximal Inhibitory Concentration (IC50) 
3.7
nM
MS-1 [Human mesothelioma] cells
Pleural malignant mesothelioma
Half Maximal Inhibitory Concentration (IC50) 
6.8
nM
Hs 578T cells
Invasive breast carcinoma
Half Maximal Inhibitory Concentration (IC50) 
8
nM
1321N1 cells
Astrocytoma
Half Maximal Inhibitory Concentration (IC50) 
18
nM
MCF-7 cells
Invasive breast carcinoma
Half Maximal Inhibitory Concentration (IC50) 
> 20
nM
MG-63 cells
Osteosarcoma
Half Maximal Inhibitory Concentration (IC50) 
> 40
nM
SH-SY5Y cells
Bone marrow neuroblastoma
Half Maximal Inhibitory Concentration (IC50) 
> 40
nM
NGP-127 cells
Neuroblastoma
Half Maximal Inhibitory Concentration (IC50) 
> 40
nM
U-87MG cells
Glioblastoma
Half Maximal Inhibitory Concentration (IC50) 
> 40
nM
HOS cells
Osteosarcoma
Half Maximal Inhibitory Concentration (IC50) 
> 40
nM
SK-BR-3 cells
Breast adenocarcinoma
Half Maximal Inhibitory Concentration (IC50) 
> 40
nM
A375 cells
Amelanotic melanoma
Half Maximal Inhibitory Concentration (IC50) 
> 40
nM
B16 cells
Melanoma
Half Maximal Inhibitory Concentration (IC50) 
> 40
nM
M3 cells
Malignant neoplasms of the mouse mammary gland
20% Maximal Inhibitory Concentration (IC20) 
0.02
nM
B78-D14 cells
Amelanotic melanoma
20% Maximal Inhibitory Concentration (IC20) 
0.02
nM
EL4 cells
Thymoma
20% Maximal Inhibitory Concentration (IC20) 
0.19
nM
T98G cells
Glioblastoma
20% Maximal Inhibitory Concentration (IC20) 
0.25
nM
IMR-32 cells
Neuroblastoma
20% Maximal Inhibitory Concentration (IC20) 
0.3
nM
U2OS cells
Osteosarcoma
20% Maximal Inhibitory Concentration (IC20) 
0.3
nM
COLO 38 cells
Amelanotic melanoma
20% Maximal Inhibitory Concentration (IC20) 
0.3
nM
MS-1 [Human mesothelioma] cells
Pleural malignant mesothelioma
20% Maximal Inhibitory Concentration (IC20) 
0.48
nM
Hs 578T cells
Invasive breast carcinoma
20% Maximal Inhibitory Concentration (IC20) 
1
nM
1321N1 cells
Astrocytoma
20% Maximal Inhibitory Concentration (IC20) 
5.3
nM
SH-SY5Y cells
Bone marrow neuroblastoma
20% Maximal Inhibitory Concentration (IC20) 
5.3
nM
MCF-7 cells
Invasive breast carcinoma
20% Maximal Inhibitory Concentration (IC20) 
5.3
nM
A375 cells
Amelanotic melanoma
20% Maximal Inhibitory Concentration (IC20) 
7.3
nM
MG-63 cells
Osteosarcoma
20% Maximal Inhibitory Concentration (IC20) 
12.4
nM
U-87MG cells
Glioblastoma
20% Maximal Inhibitory Concentration (IC20) 
> 20
nM
NGP-127 cells
Neuroblastoma
20% Maximal Inhibitory Concentration (IC20) 
> 20
nM
HOS cells
Osteosarcoma
20% Maximal Inhibitory Concentration (IC20) 
> 20
nM
SK-BR-3 cells
Breast adenocarcinoma
20% Maximal Inhibitory Concentration (IC20) 
> 20
nM
B16 cells
Melanoma
20% Maximal Inhibitory Concentration (IC20) 
> 20
nM
M3 cells
Malignant neoplasms of the mouse mammary gland
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 58.74% (Day 44) Positive GD2 expression (GD2+++/++)
Method Description
When tumors reached 50 mm3 volume. Three groups received intravenous injections of 100 ug (5 mg/kg) ch14.18-MMAE, ch14.18-MMAF, or naked antibody for five times with an interval of 4 days, and the control group was injected with PBS.
In Vivo Model EL-4 CDX model
In Vitro Model Thymoma EL4 cells CVCL_0255
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 74.95% (Day 43) Positive GD2 expression (GD2+++/++)
Method Description
When tumors reached 50 mm3 volume. Three groups received intravenous injections of 100 ug (5 mg/kg) ch14.18-MMAE, ch14.18-MMAF, or naked antibody for five times with an interval of 4 days, and the control group was injected with PBS.
In Vivo Model B78-D14 CDX model
In Vitro Model Amelanotic melanoma B78-D14 cells Homo sapiens
Revealed Based on the Cell Line Data
Click To Hide/Show 38 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.05 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Amelanotic melanoma B78-D14 cells Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.06 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Thymoma EL4 cells CVCL_0255
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.81 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Neuroblastoma IMR-32 cells CVCL_0346
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.27 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Amelanotic melanoma COLO 38 cells CVCL_3934
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.84 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Glioblastoma T98G cells CVCL_0556
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 3.30 nM Moderate GD2 expression (GD2++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Osteosarcoma U2OS cells CVCL_0042
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 3.70 nM Moderate GD2 expression (GD2++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Pleural malignant mesothelioma MS-1 [Human mesothelioma] cells CVCL_E993
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 6.80 nM Moderate GD2 expression (GD2++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Invasive breast carcinoma Hs 578T cells CVCL_0332
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 8.00 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Astrocytoma 1321N1 cells CVCL_0110
Experiment 10 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 18.00 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 11 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 20.00 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Osteosarcoma MG-63 cells CVCL_0426
Experiment 12 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 40.00 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Bone marrow neuroblastoma SH-SY5Y cells CVCL_0019
Experiment 13 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 40.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Neuroblastoma NGP-127 cells CVCL_UF75
Experiment 14 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 40.00 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
Experiment 15 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 40.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Osteosarcoma HOS cells CVCL_0312
Experiment 16 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 40.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 17 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 40.00 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Amelanotic melanoma A375 cells CVCL_0132
Experiment 18 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 40.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Melanoma B16 cells CVCL_F936
Experiment 19 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 40.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Malignant neoplasms of the mouse mammary gland M3 cells CVCL_4Y25
Experiment 20 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 0.02 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Amelanotic melanoma B78-D14 cells Homo sapiens
Experiment 21 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 0.02 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Thymoma EL4 cells CVCL_0255
Experiment 22 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 0.19 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Glioblastoma T98G cells CVCL_0556
Experiment 23 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 0.25 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Neuroblastoma IMR-32 cells CVCL_0346
Experiment 24 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 0.30 nM Moderate GD2 expression (GD2++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Osteosarcoma U2OS cells CVCL_0042
Experiment 25 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 0.30 nM High GD2 expression (GD2+++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Amelanotic melanoma COLO 38 cells CVCL_3934
Experiment 26 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 0.30 nM Moderate GD2 expression (GD2++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Pleural malignant mesothelioma MS-1 [Human mesothelioma] cells CVCL_E993
Experiment 27 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 0.48 nM Moderate GD2 expression (GD2++)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Invasive breast carcinoma Hs 578T cells CVCL_0332
Experiment 28 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 1.00 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Astrocytoma 1321N1 cells CVCL_0110
Experiment 29 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 5.30 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Bone marrow neuroblastoma SH-SY5Y cells CVCL_0019
Experiment 30 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 5.30 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
Experiment 31 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 5.30 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Amelanotic melanoma A375 cells CVCL_0132
Experiment 32 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 7.30 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Osteosarcoma MG-63 cells CVCL_0426
Experiment 33 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) 12.40 nM Low GD2 expression (GD2+)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Glioblastoma U-87MG cells CVCL_0022
Experiment 34 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) > 20.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Neuroblastoma NGP-127 cells CVCL_UF75
Experiment 35 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) > 20.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Osteosarcoma HOS cells CVCL_0312
Experiment 36 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) > 20.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 37 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) > 20.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Melanoma B16 cells CVCL_F936
Experiment 38 Reporting the Activity Date of This ADC [1]
Efficacy Data 20% Maximal Inhibitory Concentration (IC20) > 20.00 nM Negative GD2 expression (GD2-)
Method Description
Cells were sub-cultured and seeded at 5,000 cells/well in complete growth medium in 96-well tissue culture plates, and incubated at 37°C, 5% CO2 overnight. Test reagents were serially diluted and added to the cell plates (initial concentration of 100 nM). Plates were incubated at 37°C, 5% CO2 for an additional 3 d.
In Vitro Model Malignant neoplasms of the mouse mammary gland M3 cells CVCL_4Y25
References
Ref 1 Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors. J Immunother Cancer. 2022 Jun;10(6):e004646. doi: 10.1136/jitc-2022-004646.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.